Triebelhorn, J.
Schneider, J.
Spinner, C. D.
Iakoubov, R.
Voit, F.
Wagner, L.
Erber, J.
Rothe, K.
Berthele, A.
Pernpeintner, V.
Strauß, E.-M.
Renders, L.
Willmann, A.
Minic, M.
Vogel, E.
Christa, C.
Hoffmann, D.
Protzer, U.
Jeske, S. D.
Funding for this research was provided by:
Technische Universität München
Article History
Received: 26 September 2023
Accepted: 27 December 2023
First Online: 2 February 2024
Declarations
:
: JS reports grants, personal fees, and non-financial support from AbbVie, Gilead Sciences, Janssen-Cilag, GSK/ViiV Healthcare, MSD, Dr. Falk Pharma GmbH, Diasorin, Deutsche Forschungsgesellschaft (DFG) and the Central Innovation Programme for small and medium-sized enterprises (ZIM) outside the submitted work. UP is co-founder and shareholder of SCG Cell Therapy, and received personal fees from Abbott, Abbvie, Arbutus, Gilead, GSK, J&J, Roche, Sanofi, Sobi and Vaccitech. Her laboratory received grants from Hoehnle AG, SCG Cell Therapy and VirBio. All other authors declare that they have no conflicts of interest.